SCHEMBL9768272

SCHEMBL9768272

O=[N+]([O-])c1cnn(-c2ccccc2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 2/20 0.46
F2 P00734 2/20 0.41
PLAU P00749 2/20 0.41
ELANE P08246 2/20 0.41
KLKB1 P03952 1/20 0.41
KDM4E B2RXH2 3/20 0.40
HSD17B10 Q99714 2/20 0.40
HPGD P15428 3/20 0.39
ELOVL1 Q9BW60 1/20 0.39
HSP90AA1 P07900 1/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
LMNA P02545 2/20 0.38
NPC1 O15118 2/20 0.38
MAPT P10636 2/20 0.38
RAB9A P51151 2/20 0.38
ATM Q13315 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
FGFR1 P11362 1/20 0.38
ALDH1A1 P00352 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23403989 0.83 ALDH1A1 (0.44) MEN1KMT2ALMNANPC1MAPT
SCHEMBL1957390 0.79 PTGS2 (0.48) MEN1KMT2A
SCHEMBL28539628 0.77 GAA (0.41) F2PLAUELANEKLKB1KDM4E
SCHEMBL29986755 0.72 NPC1 (0.40) F2PLAUELANEKLKB1KDM4E
SCHEMBL7114840 0.69 F2 (0.53) F2PLAUELANEKLKB1KDM4E
SCHEMBL9468809 0.69 P2RX7 (0.55) P2RX7KDM4EHSD17B10HPGDELOVL1
SCHEMBL3216453 0.68 RAB9A (0.58) KDM4EHPGDMEN1KMT2ALMNA
SCHEMBL4414694 0.68 ABCG2 (0.45) KDM4EHPGDMEN1KMT2ALMNA
SCHEMBL458507 0.67 P2RX7 (0.53) P2RX7KDM4EHSD17B10HPGDELOVL1
SCHEMBL7759957 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250145642-A1 BICYCLIC HETEROARENES AND METHODS OF THEIR USE Kineta, Inc. 2025-05-08 US disclosed
CN-118946360-A Bicyclic heteroarenes and methods of use thereof 奇尼塔公司 2024-11-12 CN disclosed
EP-4444317-A2 BICYCLIC HETEROARENES AND METHODS OF THEIR USE Kineta, Inc. (US) 2024-10-16 EP disclosed
WO-2023107623-A2 BICYCLIC HETEROARENES AND METHODS OF THEIR USE Kineta, Inc. (US) 2023-06-15 WO disclosed
US-5064844-A Miticides SCHERING AGROCHEMICALS LIMITED (GB) 1991-11-12 US disclosed
EP-0350237-A2 Triazole insecticides SCHERING AGROCHEMICALS LIMITED (GB) 1990-01-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250145642-A1 BICYCLIC HETEROARENES AND METHODS OF THEIR USE TARDBP, TDP2, PSEN2 P2RX7 3433/4885F2 3373/4885PLAU 3441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.